Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Harpoon closes $15mm Series A

11 Feb 2019

Executive Summary

Harpoon Therapeutics Inc. (oncology) raised $15mm in its Series A round from affiliates of MPM Capital and the UBS Oncology Impact Fund. Harpoon was formed last year and is developing cancer therapies based on its TriTAC (Tri-specific T cell Activating Construct) platform. TriTAC antibodies bind simultaneously to cancer cells and a patient’s own T-cells, causing the T-cells to release toxins that destroy the tumor.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By